Boostrix Vaccine 2 Month (201330)

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals’ Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies interfere with the immune response to primary vaccination with Infanrix hexa and a co-administered pneumococcal conjugate vaccine given as a part of this study in infants.

Register Today!

Trial Information

Start DateDec 2016 / Jan 2017
End DateTBD
Trial Duration3-6 months
Number of Visits4
Lead CRCJessica Richer

For additional information
on this trial contact: